Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) issued its quarterly earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04), FiscalAI reports. The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.35 million.

Lucid Diagnostics Price Performance

Lucid Diagnostics stock traded down $0.03 during mid-day trading on Friday, hitting $1.05. 191,733 shares of the company’s stock traded hands, compared to its average volume of 1,042,981. The firm has a 50 day simple moving average of $1.13 and a two-hundred day simple moving average of $1.17. The stock has a market cap of $139.48 million, a price-to-earnings ratio of -1.00 and a beta of 1.22. Lucid Diagnostics has a fifty-two week low of $0.75 and a fifty-two week high of $1.80.

Insiders Place Their Bets

In other news, Director Dennis Matheis bought 100,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $1.02 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director owned 665,443 shares of the company’s stock, valued at $678,751.86. This represents a 17.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.80% of the stock is owned by insiders.

Institutional Trading of Lucid Diagnostics

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Lucid Diagnostics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock worth $4,569,000 after buying an additional 396,719 shares during the period. Geode Capital Management LLC raised its holdings in Lucid Diagnostics by 420.3% during the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after buying an additional 1,274,194 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Lucid Diagnostics by 35.7% during the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after buying an additional 22,727 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Lucid Diagnostics during the 2nd quarter worth approximately $97,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Lucid Diagnostics in the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 74.01% of the company’s stock.

Wall Street Analysts Forecast Growth

LUCD has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday. Ascendiant Capital Markets raised their price objective on Lucid Diagnostics from $7.75 to $8.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, November 5th. Wall Street Zen raised Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, BTIG Research lifted their price target on Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Friday, September 5th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $3.88.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.